As Chairman of the Department of Surgery, I oversee a department widely recognized for its expertise and innovation in cancer surgery. In addition to my administrative responsibilities, I am a surgeon specializing in prostate cancer. My expertise is in early detection, prognosis, and surgical treatment of prostate cancer. Radical prostatectomy — complete removal of the prostate — can cure many men with prostate cancer. Our team has developed surgical techniques to preserve urinary and sexual function after prostatectomy, and we continue to seek ways to improve quality of life for patients after treatment.
Not all prostate cancers progress in the same way. Many cancers pose little or no threat to life and health, while others grow aggressively and are resistant to treatment. My colleagues and I have pioneered the use of statistical models to predict both the natural progression of prostate cancer and how it will respond to treatment. These predictive tools (nomograms) help us tailor treatment for individual men according to the specific characteristics of their cancer. Today, nomograms are being used to help physicians and patients make medical decisions regarding a variety of other cancers as well, including pancreatic, lung, and breast cancer.
In 2001, I received an NIH grant to establish an ongoing Specialized Program of Research Excellence (SPORE) in prostate cancer at Memorial Sloan Kettering Cancer Center. Our SPORE has an ambitious research program focused on developing therapies appropriate for patients with different types of prostate cancer at different stages of development. We hope to achieve this by using molecular and genetic data to improve our prediction models for prostate cancer, identifying the critical mechanisms by which prostate cancer grows and spreads, and developing drugs and immunological techniques for treatment-resistant metastatic cancers.
My position at Memorial Sloan Kettering includes appointments as Head of the Prostate Cancer program, Member in the Sloan Kettering Institute’s Molecular Pharmacology Program; and the incumbent of the David H. Koch Chair. I am also a Professor in the Department of Urology at Weill Cornell Medical College and at SUNY Downstate Medical Center.
I have written many articles and book chapters and edited the Comprehensive Textbook of Genitourinary Oncology. In 2005, with Judith Kelman, I wrote Dr. Peter Scardino’s Prostate Book, a guide to prostate cancer, prostatitis, and benign prostate hyperplasia (BPH). I serve as Editor-in Chief of Nature Clinical Practice Urology, and I am an editorial board member and reviewer for several peer-reviewed journals. I am an active member of the National Academies’ Institute of Medicine and of the American Urological Association.
- Clinical Expertise: Urologic Oncology; Prostate Cancer
- Languages Spoken: English
- Education: MD, Duke University School of Medicine
- Residencies: Massachusetts General Hospital; University of California, Los Angeles, School of Medicine
- Fellowships: National Cancer Institute
- Board Certifications: Urology
Selected Books and Book Chapters
Peter Scardino’s Prostate Book: The Complete Guide to Overcoming Prostate Cancer, Prostatitis, and BPH. 2nd ed. Scardino PT, Kelman J. New York: Penguin Group; 2010.
Comprehensive Textbook of Genitourinary Oncology. 4th ed. Scardino PT, Linehan MW, Zelefsky MJ, Vogelzang NJ, eds. Philadelphia: Lippincott Williams & Wilkins; 2011.
Interventional Techniques in Uro-oncology. Ahmed HU, Arya M, Scardino PT, Emberton M, eds. London: Blackwell Publishing; 2011.
Contemporary Issues in Cancer Imaging: Prostate Cancer. Hricak H, Scardino PT, eds. Cambridge, UK: Cambridge Univ Press; 2009.
“Anatomical radical prostatectomy in the management of localized prostate cancer.” Lin DW, Eastham JA, Scardino PT. In: Management of Prostate Cancer: Advances and Controversies. Cummings KB, ed. New York: Marcel Dekker, Inc. 2005; 55-60.
“The decision-making process for prostate cancer.” Trabulsi EJ, Scardino PT, Kattan MW. In: Prostate Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ, eds. San Diego: Academic Press; 2004: 232-252.
“Carcinoma of the prostate: Radical prostatectomy.” Scardino PT, Eastham JA. In: Campbell’s Urology. 8th ed. Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Philadelphia: W.B. Saunders; 2002.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more